Family Health International Ends Viread Clinical Trial in Cameroon
August 12, 2005
Family Health International announced on Wednesday that it is terminating a clinical trial testing Gilead's antiretroviral drug Viread among commercial sex workers in Cameroon, IRIN/AllAfrica.com reports (IRIN/AllAfrica.com, 8/10). The Cameroon trial was part of a randomized, placebo-controlled clinical trial of Viread -- known generically as tenofovir -- among 2,000 HIV-negative volunteers at sites in Africa and Asia. The trial was funded with a $6.5 million grant from the Bill & Melinda Gates Foundation. However, Cameroon's Ministry of Health in February announced that it was suspending its trial arm after the advocacy group ACT UP/Paris claimed that volunteers in the study got too little information and care for their participation (Kaiser Daily HIV/AIDS Report, 2/8). According to an FHI statement, the clinic where the trials are taking place will be closed by the end of September after women have made their final visits. The five women who have contracted HIV during the Cameroon trial will have long-term access to HIV/AIDS therapy in accordance with Cameroon National AIDS Control Programme standards, FHI added.
Debate on Ethics to Continue
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.